| Clinical data | |
|---|---|
| Trade names | 速利清 |
| Other names | FPF-1070, 脑蛋白水解物 [cerebroprotein hydrolysate] |
| AHFS/Drugs.com | [2] |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Cerebrolysin (developmental code name FPF-1070) is an experimental mixture of enzymatically-treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). [3] [4] Although it is under preliminary study for its potential to treat various brain diseases, it is used as a therapy in dozens of countries in Eurasia.
Cerebrolysin has been studied for potential treatment of several neurodegenerative diseases, with only preliminary research, as of 2023. [4] No clear benefit in the treatment of acute stroke has been found, and an increased rate of spontaneous adverse effects requiring hospitalization is reported. [4] Some positive effects have been reported when cerebrolysin is used to treat vascular dementia. [5]
A 2023 review indicated that cerebrolysin or cerebrolysin-like peptide mixtures from cattle brain likely provide no benefit for preventing all-cause death in acute ischemic stroke, and that higher quality studies are needed. [4] In addition, cerebrolysin might cause a higher rate of spontaneous adverse events requiring hospitalization. [4]
Studies of ischemic stroke in Asian subpopulations found an absence of benefit. [6] A 2020 study suggested a lack of benefit in hemorrhagic stroke related to cerebral aneurysm. [7]
Reviews of preliminary research indicate a possible improvement in cognitive function using cerebrolysin for vascular dementia and Alzheimer's disease, although further high-quality research is needed. [5] [8]
Early studies have suggested potential use of cerebrolysin with a wide variety of neurodegenerative disorders, including traumatic brain injury, [9] [10] schizophrenia, [11] multiple sclerosis, [12] cerebral palsy [13] and spinal cord injury [14] [15] although research is still preliminary.
Upon injection, adverse effects of cerebrolysin include nausea, dizziness, headache, and sweating. [1] It is not recommended for use in people with epilepsy, kidney disease, or hypersensitivity to the compound constituents. [1]
In trials studying the use of cerebrolysin after acute stroke, there was no increased risk of "serious adverse events" requiring hospitalization. [4] These were specifically defined as "...any untoward medical occurrence that, at any dose, resulted in death, [was] life-threatening, required inpatient hospitalisation or resulted in prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, [was] a congenital anomaly/birth defect, or [was] a medically important event or reaction". [4]
Laboratory studies indicate there may be neurotrophic effects of cerebrolysin similar to endogenous mechanisms, although its specific molecular effects are not clear. [16]
Cerebrolysin is given by injection. [1] Some of the peptides in cerebrolysin are short-lived once in the blood (for example, the half-life of BDNF is only 10 minutes). [17]
Although cerebrolysin is used in Russia, Eastern European countries, China, and other Asian countries, its status as a government-approved drug is unclear. [4] It is only available by prescription from a physician. [1] According to the manufacturer, the European Medicines Agency has declared cerebrolysin as safe. [1]
It is not an approved drug in the United States. [18] [19]